Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Enters Formulary Fray: Agency Plans Analysis For E-Rx Standards

Executive Summary

FDA will submit comments to HHS analyzing the U.S. Pharmacopoeia draft Medicare formulary guidelines and the Veterans Administration drug classification for compatibility with electronic prescribing platforms

You may also be interested in...



E-Prescribing For Controlled Substances Needs Attention, HHS Panel Says

HHS and the Justice Department need to collaborate to ensure that controlled substances are cleared for electronic prescribing, the National Committee on Vital & Health Statistics said

E-Prescribing For Controlled Substances Needs Attention, HHS Panel Says

HHS and the Justice Department need to collaborate to ensure that controlled substances are cleared for electronic prescribing, the National Committee on Vital & Health Statistics said

FDA, CMS To Begin Collaborating On Drug Safety Data Collection In 2005

FDA will begin using drug safety information collected by the Centers for Medicare & Medicaid Services in 2005

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel